文献速递分子诊断临床微生物质量管理与危急值

SARS-CoV-2测序外部质量评估:ESGMD-SSM跨15个欧洲实验室试点试验

External Quality Assessment of SARS-CoV-2 Sequencing: an ESGMD-SSM Pilot Trial across 15 European Laboratories.
PubMed 文献 · J Clin Microbiol · 2021-11-10

由ESCMID ESGMD与SSM发起的首个SARS-CoV-2全基因组测序外部质量评估试点,向15家临床实验室发放10份不同病毒载量样本,实验室自选测序与生信分析流程。多数实验室能获得全基因组,测序深度差异可达100倍;大多数报告标准共识良好,但谱系与簇分配及变异调用存在不一致,主因包括数据缺失、生信选择和数据解读。试点总体成功,后续应完善变量与报告格式并纳入污染/少数变异评估。

要点

  • 多数参评实验室可对全部样本产出全基因组,但测序深度中心间差异可达100倍。
  • 大多数报告标准共识良好,但谱系与簇分配及变异调用存在不一致。
  • 不一致主因包括数据缺失、生信分析选择和数据解读差异。

核心结论

  • 该SARS-CoV-2测序外部质量评估试点总体成功,显示参评实验室测序质量较高,并在问题出现时提供有价值反馈以改进实验室测序设置。

研究设计与样本

  • 由ESCMID ESGMD与SSM发起的首个SARS-CoV-2全基因组测序外部质量评估试点,向15家临床实验室发放10份不同病毒载量样本,实验室自选测序方法与生信分析。

主要发现

  • 多数参评实验室能对所有样本生成全基因组,各中心测序深度差异可达100倍。
  • 大多数报告标准共识很好,但谱系和簇分配存在少数差异,变异调用也存在不一致。
  • 差异主因包括数据缺失、生信分析选择和数据解读。

关键数值与推荐

  • 比较关键方面包括识别单核苷酸多态性(SNPs)和插入缺失(indels)、Pango谱系以及样本间簇。
  • 各中心测序深度差异可达100倍。

临床怎么用

  • 参评实验室可据此识别测序与生信分析中的问题并改进实验室测序设置。

局限性

  • 后续更大规模外部质量评估应改进变量与报告格式的定义。
  • 污染和/或少数变异应作为进一步评估方面。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This first pilot trial on external quality assessment (EQA) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) whole-genome sequencing, initiated by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Genomic and Molecular Diagnostics (ESGMD) and the Swiss Society for Microbiology (SSM), aims to build a framework between laboratories in order to improve pathogen surveillance sequencing. Ten samples with various viral loads were sent out to 15 clinical laboratories that had free choice of sequencing methods and bioinformatic analyses. The key aspects on which the individual centers were compared were the identification of (i) single nucleotide polymorphisms (SNPs) and indels, (ii) Pango lineages, and (iii) clusters between samples. The participating laboratories used a wide array of methods and analysis pipelines. Most were able to generate whole genomes for all samples. Genomes were sequenced to various depths (up to a 100-fold difference across centers). There was a very good consensus regarding the majority of reporting criteria, but there were a few discrepancies in lineage and cluster assignments. Additionally, there were inconsistencies in variant calling. The main reasons for discrepancies were missing data, bioinformatic choices, and interpretation of data. The pilot EQA was overall a success. It was able to show the high quality of participating laboratories and provide valuable feedback in cases where problems occurred, thereby improving the sequencing setup of laboratories. A larger follow-up EQA should, however, improve on defining the variables and format of the report. Additionally, contamination and/or minority variants should be a further aspect of assessment.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Wegner F, Roloff T, Huber M, et al. External Quality Assessment of SARS-CoV-2 Sequencing: an ESGMD-SSM Pilot Trial across 15 European Laboratories. J Clin Microbiol. 2021. PMID: 34757834. doi:10.1128/JCM.01698-21

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。